Ongoing Study Finds Ikervis to be Effective Treatment for Dry Eye Disease
New data presented at the 2019 European Society of Cataract and Refractive Surgeons (ESCRS) congress showed that Santen’s Ikervis (ciclosporin) yielded significant improvements in corneal fluorescein staining (CFS).
The ongoing, non-interventional prospective study evaluated the effectiveness of cyclosporine for treating severe keratitis in patients with dry eye disease who previously failed to respond to artificial tear treatments. Three-month data were presented at the meeting.
Results showed that, at baseline, 162 patients had a mean CFS score of 2.64. This score improved to 1.77 in 94 patients at week 4 (P < .001) and 1.36 in 117 patients at week 12 (P < .001). Improvements in CFS score were seen at week 4 in 71.8% of patients. At week 12, 75% of patients experienced CFS score improvements. Conjunctival erythema was reduced in 45.8% of patients by week 12.
Most physicians found Ikervis to be more effective than previous treatments.
You can read more here.